Tempus AI, Inc.: Business Overview, Financials & Competitive Analysis

Tempus AI, Inc. Overview

Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, offering AI-enabled precision medicine solutions to physicians to deliver personalized patient care and facilitating discovery, development and delivery of optimal therapeutics. The company provides next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.

Strategic Profile

Tempus operates a comprehensive platform including Next (oncology algorithms), Hub (test ordering and results platform), and Lens (data analytics platform), with strategic collaborations with AstraZeneca, Pathos AI, Personalis, and Whitehawk Therapeutics to develop therapeutic programs. The company reported record Total Contract Value exceeding $1.1 billion as of December 31, 2025, with Data and applications revenue of approximately $316 million (31% YoY growth) and net revenue retention of approximately 126%.

Competitive Landscape

Tempus focuses on bringing artificial intelligence and machine learning to healthcare across oncology, neuropsychiatry, cardiology, infectious disease, and radiology. Key competitors include traditional diagnostic labs (LabCorp, Quest Diagnostics), genomic testing companies (Guardant Health, Foundation Medicine), and AI healthcare startups (Paige, Recursion Pharmaceuticals). Tempus differentiates through comprehensive data integration combining genomic, clinical, and imaging data with proprietary AI algorithms.

Industry Context

Tempus AI, Inc. operates in Healthcare Technology / Precision Medicine / AI Diagnostics.

Key facts

Founded: 2015 · Headquarters: Chicago, IL · Employees: 2,400 · Revenue: $1.55B · Market cap: $9.25B